Stock info Molecular Medicine | Filter  Basic-Info

Molecular Medicine

Molecular Medicine's main office is based in Milan. Between 2006 and 2016 the global biotech companies gained around 59 percent. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

The past year gave good returns for Molecular Medicine investors

Over the last 12 months (from December 2015 till December 2016), that were profitable period for the investors in Molecular Medicine, the stock gained around 22 percent. The period between August 2011 and August 2016 was a profitable period for the investors. The stock rose on average 13 percent. Molecular Medicine's revenues between 2011 and 2015 were very volatile through the time and moved between 4,59 million euros and 13,58 million euros. During 2011 and 2015 Molecular Medicine's net results were very volatile and fluctuated between -21,57 million euros and -20,78 million euros.

The Italian company didn't pay out any dividends (in the past 5 years).

Molecular Medicine financed with a quite low debt position

As per the end of 2015 the Italian company's balance sheet equaled 56,89 million euros. Of the total balance sheet 24,96 million euros (43,87 percent) was financed by debt. As per the end of 2015 Molecular Medicine's price/earnings-ratio equaled -6. So investors paid for 1 stock -6 times the earnings per share of 2015. Based on it's price/earnings-ratio and dividend yield the Italian stock can be seen as a value stock.

At the end of 2015 the biotech company's market capitalization (the number of shares times the market price) equaled around 139,03 million euros. At the end of 2015 the Italian company had around 375,77 million stocks listed on the exchanges.

On this page you can find all Molecular Medicine's financial reports. More information about Molecular Medicine can be found it's website. .